Drug Trial Radar · NCT02157376
Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients
Last checked: Nov 21, 2026Latest source record: Mar 10, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
343
Actual
Start
Jul 2014
Primary completion
Feb 2016
Study completion Feb 2016
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 6, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The efficacy of esomeprazole will be compared versus cimetidine (a drug that previously demonstrated prevention of bleeding events) during treatment period in proportion of patients for the prevention of upper GI bleeding.
Conditions
- Stress Ulcer Prophylaxis
Interventions
EsomeprazoleDrug
iv esomeprazole 30 min intermittent infusions given for maximum 14 days
CimetidineDrug
iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation PhaseTime frame: 1-14 days
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Baotou, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Fuzhou, China
Research Site
Guangzhou, China
Research Site
Guilin, China
Research Site
Haikou, China
Research Site
Qingdao, China
Research Site
Shanghai, China
Research Site
Shenzhen, China
Research Site
Tianjin, China
Research Site
Ürümqi, China
Research Site
Xi'an, China
Research Site
Zhanjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.